CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAS). (April 2017) - Garcia-Manero, G.; Savona, M.R.; Gore, S.D.; Scott, B.L.; Cogle, C.R.; Boyd, T.; Conkling, P.; Hetzer, J.; Dong, Q.; Kumar, K.; Ukrainskyj, S.M.; Skikne, B.S.